SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0600+16.5%Nov 26 3:10 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard Williams who wrote (11368)6/26/2012 7:56:51 AM
From: NTTG1 Recommendation  Read Replies (1) of 13111
 
Yea, I saw that. But disease control is not what the FDA is looking for, and in a comparator controlled trial the 'stable disease group' would likely be a wash between the two arms; CR and PR is where the FDA is looking. Also thought it was best not to draw attention to the culled patient data analysis; 5 stage III and six stage IV were considered 'unevaluable' since their disease was deemed (by what criteria?) to be progressing too fast.

Sounds like spit ball analysis
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News